hackint0sh/New-Dataset huggingface dataset:
PET examinations will be performed on both fatigued and non-fatigued. We will utilize the second generation TSPO radioligand \[ 11C\]PBR28 as well as the SV2A radioligand \[ 11C\]UCB-J, both showing high signal-to-noise ratio and adequate test-retest properties. conditions: Fatigue conditions: Cognitive Dysfunction studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 30 type: ESTIMATED measure: Results of cognitive tests measure: Potential biomarkers for fatigue and cognitive dysfunction measure: PET results measure: Global analyses of the neural connections sex: ALL minimumAge: 20 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Karolinska status: RECRUITING city: Stockholm zip: 14186 country: Sweden name: Ksenia Boriskina, MD role: CONTACT phone: 0858580675 email: ksenia.boriskina@regionstockholm.se name: Kirsti Niemelä, study nurse role: CONTACT name: Katarina Le Blanc, professor role: PRINCIPAL_INVESTIGATOR lat: 59.33258 lon: 18.0649 hasResults: False
nctId: NCT06363383 id: MB-001-101 briefTitle: A Phase 1 Study to Evaluate the Safety of an Oral Biologic in Healthy Participants overallStatus: RECRUITING date: 2024-05-09 date: 2025-05 date: 2025-05 date: 2024-04-12 date: 2024-04-18 name: Mage Biologics class: INDUSTRY name: Alimentiv Inc. briefSummary: The goal of this clinical trial is to learn if the oral biologic MB-001 is safe in healthy volunteers. The main questions it aims to answer are:
Participants will receive a single or five daily doses of the drug or placebo and will be asked to stay in the clinic for five days following the last dose. conditions: Ulcerative Colitis studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: two-stage, single-center, double-blinded, randomized, placebo-controlled primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: double-blinded using matching placebo capsules containing matching pellets whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 48 type: ESTIMATED name: MB-001 measure: Incidence and severity of adverse events (AEs) measure: Clinically significant changes from baseline in vital signs measure: Clinically significant changes from baseline in physical examination findings measure: Clinically significant changes from baseline in clinical laboratory assessments measure: Clinically significant changes from baseline in ECG parameters measure: Area under the concentration-time curve measure: Maximum plasma concentration measure: Time to reach observed maximum plasma concentration after administration measure: Trough concentration sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: CMAX status: RECRUITING city: Adelaide state: South Australia zip: 5000 country: Australia name: Jessica Lehman role: CONTACT phone: +61 8 7088 7900 email: cmax@cmax.com.au lat: -34.92866 lon: 138.59863 hasResults: False
nctId: NCT06363370 id: KXZY-GB05-201 briefTitle: Human Interferon α1b Inhalation Solution Against Respiratory Syncytial Virus in Children With Lower Respiratory Tract Infections overallStatus: RECRUITING date: 2024-03-27 date: 2026-06-30 date: 2026-06-30 date: 2024-04-12 date: 2024-04-12 name: Kexing Biopharm Co., Ltd. class: INDUSTRY briefSummary: To evaluate the efficacy and safety of interferon α1b (GB05) in the treatment of children under 2 years of age with respiratory syncytial virus infection. conditions: Respiratory Syncytial Virus Infections studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 322 type: ESTIMATED name: Human interferon α1b Inhalation Solution name: Inhalation Solution Placebo measure: Wang bronchiolitis score chanced by percentage from baseline measure: Wang bronchiolitis score chanced by percentage from baseline measure: Wang bronchiolitis score of 0 in proportion measure: Wang bronchiolitis score total score < 5 points measure: Wang bronchiolitis score, the first time the total score reaches < 5 points measure: RSV viral load sex: ALL minimumAge: 2 Months maximumAge: 2 Years stdAges: CHILD facility: Children's Hospital, Capital Institute of Pediatrics status: RECRUITING city: Beijing state: Beijing zip: 100000 country: China name: Ling Cao, MD role: CONTACT phone: 13910610319 lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06363357 id: 24B-007-0000 briefTitle: The Effect of a Muscle-mimicking, Fabric-type Shoulder Orthosis on Functional Movements of the Upper Limb in Patients With Duchenne Muscular Dystrophy overallStatus: NOT_YET_RECRUITING date: 2024-04-20 date: 2025-12-31 date: 2025-12-31 date: 2024-04-12 date: 2024-04-12 name: Seoul National University Hospital class: OTHER briefSummary: The goal of this clinical trial is to investigate the effect of a muscle-mimicking, fabric-type shoulder orthosis on functional movements of the upper limb in patients with Duchenne muscular dystrophy.
Researchers will compare Duchenne muscular dystrophy patients before and while wearing and operating the shoulder orthosis to see if there are any significant effects on variables such as upper limb function, range of motion, functional workspace, goal attainment scale, and surface electromyography. conditions: Muscular Dystrophy, Duchenne conditions: Orthotic Devices conditions: Upper Extremity studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: This study compares variables before and after wearing the shoulder orthosis in patients with Duchenne muscular dystrophy. primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 30 type: ESTIMATED name: Shoulder orthosis measure: Performance of the upper limb module 2.0 (PUL 2.0) measure: Active Range of motion measure: Functional workspace measure: Goal Attainment Scale (GAS) measure: Surface electromyography (sEMG) sex: ALL minimumAge: 10 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Seoul National University Hospital city: Seoul state: Jongno-gu zip: 03080 country: Korea, Republic of name: Woo Hyung Lee, MD, Ph.D role: CONTACT phone: +82-2-2072-4178 email: whlee909@snu.ac.kr lat: 37.566 lon: 126.9784 hasResults: False
nctId: NCT06363344 id: APHP231022 id: IDRCB: 2023-A00660-45 type: REGISTRY domain: IDRCB ANSM briefTitle: Follow-up in Pediatric Intensive Care Unit acronym: APRELAREA overallStatus: RECRUITING date: 2024-04-01 date: 2025-04-01 date: 2025-09-01 date: 2024-04-12 date: 2024-04-15 name: Assistance Publique - Hôpitaux de Paris class: OTHER briefSummary: Background In developed countries, mortality rates in pediatric intensive care units (PICUs) are around 4% and thus, most children admitted to these units survive. However, some pediatric survivors experience long-term morbidity (cognitive, psychological, social and/or physical disorders) associated with their intensive care stay. Currently in France, there are no recommendations for the management of these patients and most of them do not have standardized follow-up.
Perspectives Compare the benefit of this systematic, multi professional and comprehensive management of pediatric patients after PICU discharge versus standard of care conditions: Intensive Care Psychosis studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 120 type: ESTIMATED name: Questionnaires : PHQ-9 (Kroenke, 2001), the PSC (Sheldrick, 2012), the ASQ-SE (Squires, 2015), the PedsQL (Varni, 1999) measure: Emotional and behavioral problem of the children measured by the PSC questionnaire (Sheldrick, 2012) measure: Mental disorders measured by the PHQ-9 (Kroenke, 2001) questionnaire measure: Social-emotional development measured by the ASQ-SE (Squires, 2015) questionnaire measure: Pediatric Quality of Life measured by the the PedsQL (Varni, 1999) questionnaire sex: ALL minimumAge: 1 Day maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: Robert Debre Hospital status: RECRUITING city: Paris zip: 75019 country: France name: Michaël LEVY, MD, PhD role: CONTACT phone: +33.1.40.03.40.98 email: michael.levy@aphp.fr name: Enora LE ROUX, PhD role: CONTACT phone: +33.1.40.03.23.66 email: enora.leroux@aphp.fr lat: 48.85341 lon: 2.3488 hasResults: False
nctId: NCT06363331 id: 2020I054 briefTitle: Efficacy of the Social Cognition Rehabilitation Program E-motional Training in the Treatment of Patients With Substance-related Disorders overallStatus: COMPLETED date: 2022-03-01 date: 2022-12-01 date: 2023-12-30 date: 2024-04-12 date: 2024-04-12 name: Fundacin Biomedica Galicia Sur class: OTHER briefSummary: Drug use, substance use disorders (SUD) and other addictive behaviors are problems of enormous socio-health impact that still require a great research effort to improve the diagnostic and therapeutic procedures used in healthcare practice.
To replicate the RCT carried out in schizophrenia in patients with SUD with difficulties in RE or ToM, in addition to searching for a biomarker or a pattern of them that predict the patient profile that will benefit from the training, using advanced LC-ESI proteomics techniques. MS/MS in saliva since previous studies in a population with schizophrenia, subjected to different neurorehabilitation therapies. It is also intended to subsequently improve the instrument (ET®) through the implementation of big data analysis and machine learning and the introduction of automated user management. At this level, the objective is to determine, after the first games, the type of game and the intensity required to improve the user's performance until it reaches normality.
From the perspective of the State Plan for Scientific and Technical Research and Innovation, this project combines CLINICAL AND TRANSLATIONAL RESEARCH, based on the evidence of scientific and technological knowledge, and the use of ENABLING TECHNOLOGIES of e-health in the area of Health Services. Health for people with SUD. conditions: Social Behavior studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 231 type: ACTUAL name: Emotional Training measure: Assess the presence of dysfunctions in the subdomains of social cognition measure: Accuracy and efficacy of ET® in patients with SDB sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Galicia Sur Health Research Institute (IISGS) - Hospital Álvaro Cunqueiro city: Vigo state: Pontevedra zip: 36213 country: Spain lat: 42.23282 lon: -8.72264 facility: Galicia Sur Health Research Institute city: Vigo state: Pontevedra zip: 36213 country: Spain lat: 42.23282 lon: -8.72264 hasResults: False
nctId: NCT06363318 id: 0003 briefTitle: Comparison of Open and Laparoscopic Appendectomy in Pediatric Population acronym: Appendicitis overallStatus: COMPLETED date: 2019-07-01 date: 2019-11-30 date: 2019-11-30 date: 2024-04-12 date: 2024-04-15 name: King Edward Medical University class: OTHER briefSummary: Introduction: In the era of minimally invasive surgery, changing trends are towards laparoscopic surgery, first introduced in 1983. Now the preferred operation for children with appendicitis, laparoscopic appendectomy is associated with a reduced risk of wound infection, less postoperative pain and shorter hospital stay as compared to open appendectomy.
Objectives: To compare the outcome of open and laparoscopic appendectomy in children presenting with appendicitis in terms of operative time, postoperative pain, wound infection and hospital stay. conditions: Appendicitis Acute studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: children were randomly divided in two groups. In group A, laparoscopic appendectomy was done. In group B, open appendectomy was done primaryPurpose: TREATMENT masking: NONE count: 100 type: ACTUAL name: Laparoscopic appendicectomy measure: Operative time measure: wound infection measure: Hospital stay measure: Postoperative pain sex: ALL minimumAge: 7 Years maximumAge: 12 Years stdAges: CHILD facility: Muhammad Sharif city: Lahore state: Punjab zip: 53711 country: Pakistan lat: 31.558 lon: 74.35071 hasResults: False
nctId: NCT06363305 id: 2402-1139 briefTitle: Impact of Sex in the Effect of Dietary Capsaicin on Cardiovascular Health overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-12-01 date: 2025-12-31 date: 2024-04-12 date: 2024-04-18 name: Skidmore College class: OTHER name: American Heart Association briefSummary: The investigators long-term goal is to better understand novel interventions to promote cardiovascular health in humans. The goal of the proposed research is to investigate whether there is sex-specificity in the effects of dietary capsaicin on mechanisms regulating nitric oxide (NO) bioavailability, its effect on key markers of cardiovascular (CV) health, including BP, macro- and microvascular function, and arterial stiffness. This knowledge will provide critical insight into the effects of dietary capsaicin on CV health and will guide future trials. conditions: Pre Hypertension conditions: Hypertension studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Parallel: Participants are randomly assigned to one of two groups in parallel for the duration of the study primaryPurpose: BASIC_SCIENCE masking: TRIPLE maskingDescription: The capsules will be placed into solid white color bottles, and labeled discreetly by a third party not directly involved with the research. whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 80 type: ESTIMATED name: Dietary capsules measure: Blood Pressure and Vascular Stiffness measure: Heart Rate (HR) and HR variability (HRV) measure: Flow Mediated Dilation measure: Passive Leg Movement Hyperemia measure: Near Infrared Spectroscopy (NIRS) Vascular Occlusion Test measure: Urinary Capsaicinoids measure: Blood Lipids sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Skidmore College city: Saratoga Springs state: New York zip: 12866 country: United States name: Stephen Ives, Ph.D. role: CONTACT phone: 518-580-8366 email: sives@skidmore.edu lat: 43.08313 lon: -73.78457 hasResults: False
nctId: NCT06363292 id: SOPH231-1221/I briefTitle: Study to Evaluate the Safety and Tolerability of PRO-231 Ophthalmic Solution Versus VIGAMOXI® on the Ocular Surface of Healthy Subjects. overallStatus: RECRUITING date: 2024-01-30 date: 2024-05-30 date: 2024-05-30 date: 2024-04-12 date: 2024-04-15 name: Laboratorios Sophia S.A de C.V. class: INDUSTRY briefSummary: This is a phase I clinical study evaluating the safety and tolerability of PRO-231 ophthalmic solution through the incidence of unexpected adverse events, incidence of conjunctival hyperemia and chemosis, changes in Best Corrected Visual Acuity (BCVA), changes in ocular surface integrity, compared to VIGAMOXI®. conditions: Ophthalmological Agent Toxicity conditions: Bacterial Conjunctivitis studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Phase I, controlled, comparative, parallel-group, single-blind, single-center, controlled clinical trial. primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: Single-blind whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 36 type: ESTIMATED name: PRO-231 name: VIGAMOXI® measure: Incidence of unexpected adverse events related to the interventions measure: Incidence of conjunctival hyperemia and chemosis measure: Changes in Best Corrected Visual Acuity (BCVA) measure: Changes in the integrity of the ocular surface (fluorescein staining) measure: Changes in the Ocular Comfort Index (OCI) score between interventions. measure: Incidence of unexpected adverse events (excluding conjunctival hyperemia and chemosis) measure: To assess the tolerability of PRO-231 ophthalmic solution sex: ALL minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: IIMET Investigación e Innovación en Medicina Traslacional status: RECRUITING city: Guadalajara state: Jalisco zip: 44610 country: Mexico name: Alejandro González, MD role: CONTACT lat: 20.66682 lon: -103.39182 hasResults: False
nctId: NCT06363279 id: 2024/24JAN/044 briefTitle: Validation of the French ATI Scale and Predisposition to Use Technological Tools in Rehabilitation. overallStatus: RECRUITING date: 2024-04-04 date: 2024-09 date: 2024-10 date: 2024-04-12 date: 2024-04-12 name: Cliniques universitaires Saint-Luc- Université Catholique de Louvain class: OTHER briefSummary: Aim of the study: The first aim of this study is to validate the translation of the Affinity for Technology Interaction (ATI) questionnaire. This questionnaire was developed in English by Franke, Attig and Wessel in 2019. It consists of 9 items and was developed to assess a person's tendency to actively engage in technological interaction, or the ease with which a person uses technological tools. Currently, the questionnaire has been translated into French by our research team according to good practice recommendations (Guillemin, Bombardier and Beaton, 1993; Tsang et al., 2017), but this French version has not yet been validated. To validate the translation of a questionnaire, it is necessary to have it completed by a large number of subjects from the population of interest. In neurorehabilitation, measuring this affinity will make it possible to better identify patients who are more likely to adhere to tele-rehabilitation and thus direct them towards this type of treatment as a complement to conventional rehabilitation.
The second objective is to determine the extent to which the general population is prepared to use technological tools as part of their rehabilitation. The aim is to gain a better understanding of the profile of people who could potentially benefit from tele-rehabilitation. Accessibility to the technologies, their expectations and barriers will also be explored as part of this study. conditions: Stroke studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 1000 type: ESTIMATED name: Conducting questionnaires measure: ATI - affinity technology interaction scale measure: Scale for assessing a person's readiness to use technological tools as part of their rehabilitation sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Clinique Universitaires Saint-Luc status: RECRUITING city: Brussel state: Woluwé-Saint-Lambert zip: 1200 country: Belgium name: Thierry Lejeune, MD, PhD role: CONTACT phone: +3227641648 email: thierry.lejeune@saintluc.uclouvain.be name: Mathilde Van Durme role: CONTACT phone: +3227641675 email: mathilde.vandurme@saintluc.uclouvain.be lat: 50.85045 lon: 4.34878 hasResults: False
nctId: NCT06363253 id: CIRB Ref: 2023/2073 briefTitle: Pilot Study of the Human Metagenome in Metabolic Diseases overallStatus: RECRUITING date: 2023-08-14 date: 2026-12-31 date: 2027-12-31 date: 2024-04-12 date: 2024-04-12 name: Sengkang General Hospital class: OTHER name: Singapore General Hospital name: Lee Kong Chian School of Medicine, Nanyang Technological University name: Duke-NUS Graduate Medical School briefSummary: This is a cohort study to understand the role of the human metagenome, and associated metabolites, in health and in various diseased states, in particular obesity as well as sarcopenia.
We hope to uncover various differences and signatures in the metagenome and metabolome in various diseased states, with potential future therapeutic applications in personalised medicine. conditions: Obesity conditions: Sarcopenia conditions: Sarcopenic Obesity conditions: Chronic Inflammation conditions: Metabolic Syndrome studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 600 type: ESTIMATED name: No specific intervention measure: Metagenomic alterations measure: Metabolomic alterations sex: ALL minimumAge: 21 Years maximumAge: 99 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sengkang General Hospital status: RECRUITING city: Singapore zip: 544886 country: Singapore name: Koy Min Chue role: CONTACT phone: 69305000 email: chue.koy.min@singhealth.com.sg lat: 1.28967 lon: 103.85007 hasResults: False
nctId: NCT06363240 id: CBBLCIP001 briefTitle: Evaluation of Broadband Light Treatment for Solar Lentigines overallStatus: RECRUITING date: 2024-03-12 date: 2024-12-20 date: 2025-01-30 date: 2024-04-12 date: 2024-04-12 name: Sciton class: INDUSTRY briefSummary: Broadband light treatment for Solar Lentigines conditions: Solar Lentigo studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: Broadband Light measure: Changes in skin post treatment sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sanctuary Plastic Surgery status: RECRUITING city: Boca Raton state: Florida zip: 33431 country: United States name: Jonathan Cook, MD role: CONTACT lat: 26.3669 lon: -80.13033 hasResults: False
nctId: NCT06363227 id: ANEST-0003 briefTitle: Postoperative Pain After Implementation of Standardized Pain Therapy Management in Orthopaedic Patients acronym: PAIN overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-02 date: 2025-04 date: 2024-04-12 date: 2024-04-16 name: Schulthess Klinik class: OTHER briefSummary: The aim of this study is to examine the impact of implementing a standardized pain therapy protocol and their components on postoperative pain trajectories and postoperative outcomes such as increased opioid consumption and to compare it for different orthopaedic operations, i.e. major shoulder, hip, knee und spine surgery. conditions: Postoperative Pain, Acute studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 12000 type: ESTIMATED name: Standardized pain management measure: Perioperative pain trajectories measure: Increased risk for postoperative pain measure: Total amount of opioids administered measure: Correlation of pain trajectories and patient reported outcome measures (e.g. postoperative nausea and vomiting) sex: ALL minimumAge: 16 Years maximumAge: 99 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06363214 id: ANEST-0002 briefTitle: Impact of Patient Blood Management (PBM) at the Schulthess Clinic acronym: PBM overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-02 date: 2025-04 date: 2024-04-12 date: 2024-04-16 name: Schulthess Klinik class: OTHER briefSummary: Aim of this study is to analyze the transfusion requirements of allogenic blood products at the Schulthess Clinic for patients that had major orthopedic or major spine surgery between 2019 and 2024 order to identify patients at risk for transfusion. Moreover, impact of transfusion requirements and other measures of PBM on patient outcomes will be assessed. These data are required to further improve PBM at the Schulthess Clinic. conditions: Patient Blood Management studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 16000 type: ESTIMATED name: Patient blood management measure: Perioperative transfusion rates measure: Risk factors for perioperative transfusion Risk factors for perioperative transfusion Risk factorsfor perioperative transfusion measure: Perioperative rates of coagulation products administered measure: Clinical outcomes sex: ALL minimumAge: 16 Years maximumAge: 99 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False